Clinical evidence · Cited record
PT-141 Research: The Trials and the Mechanistic Record
Two Phase 3 RCTs, a 52-week extension, an fMRI mechanism study, preclinical desire models, and the obesity finding — each tagged to its study and read at its true evidence strength.
The short version
The PT-141 research record is unusually deep for a peptide: two large human trials — the RECONNECT clinical trials — a year-long follow-up, a brain-imaging study, and a stack of animal work. The human trials show the drug raises sexual desire in premenopausal women with HSDD by a real but small margin, and that nausea is the main downside. The animal and imaging studies explain why it works — it acts on a brain circuit for desire. Other findings (weight, erectile signals in men) exist but are not approved uses. Below, each study is reported with what it measured, in which species, and how strong the evidence is.
RECONNECT: the two pivotal Phase 3 trials
Two identical Phase 3 randomized controlled trials — the RECONNECT program (studies 301 and 302), 1,267 premenopausal women with HSDD — are the basis of approval [3]. Bremelanotide 1.75 mg subcutaneous as-needed produced a statistically significant improvement in sexual desire (integrated FSFI desire +0.35, P<.001) and a statistically significant reduction in desire-related distress (integrated FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. Both coprimary endpoints were met in both trials. The most common adverse events were nausea, flushing, and headache [3].
The honest framing is that these effects are statistically real and clinically modest. Critical re-analyses in the literature have argued the desire and distress effects, while significant, are small, and have questioned the outcome measures and the clinical meaningfulness of the change [3]. The trials succeeded on their endpoints; the size of the benefit is a legitimate and ongoing debate.
The 52-week extension: durability and the safety profile
The open-label extension of RECONNECT followed 684 women for up to 52 weeks [4]. Sexual-desire improvements were sustained and no new safety signals emerged [4]. The extension is also the cleanest source for the long-term adverse-event frequencies: the most common drug-related treatment-emergent events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea was the principal tolerability issue and a notable driver of discontinuation [4]. The full adverse-event picture, including the cardiovascular signal and hyperpigmentation, is set out under tolerability and adverse events.
The fMRI study: mechanism in the human brain
A randomized, double-blind, placebo-controlled crossover fMRI study in 31 premenopausal women with HSDD provided direct human mechanistic evidence [5]. MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli — enhanced amygdala-insula functional connectivity and cerebellar/supplementary-motor activity [5]. This is the study that anchors the 'acts on the brain' claim in measured human neuroimaging rather than inference [5].
Preclinical desire models: where the central hypothesis came from
The central-mechanism hypothesis was built in animals before it was tested in people. In female rats, the melanocortin agonist selectively stimulated appetitive solicitational sexual behavior without affecting lordosis, pacing, or general motor activity — the first pharmacological agent reported to act on appetitive female sexual behavior [2]. Systemic administration in rats and nonhuman primates produced erections and activated hypothalamic neurons, consistent with a central site of action [1].
Later circuit work sharpened the model. In female mice, MC4R signaling in Sim1-expressing neurons permitted sexual receptivity [11]. The preclinical CNS evidence on female sexual function has been consolidated in review [7], and the neurobiology of bremelanotide for HSDD in premenopausal women has been synthesized to connect MC4R activation in hypothalamic and limbic circuits to desire pathways [9].
Does PT-141 cause weight loss?
In two Phase 1 research trials in obese premenopausal women, high-frequency MC4R agonism reduced caloric intake and body weight — about -1.3 kg versus placebo over 16 days (P<.0001), with a roughly 400 kcal/day reduction in intake — reflecting MC4R's role in appetite [10]. This is a research finding at a high-frequency dosing protocol, not an approved use and not a weight-loss indication [10].
Recent literature, 2024-2026
The recent record is largely consolidation and mechanistic refinement. A 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in ventral tegmental area dopamine neurons but reported that bremelanotide did not enhance sexual reward (conditioned place preference), suggesting it does not act on the VTA-nucleus accumbens reward circuit [12]. A 2025 review of novel pharmacologic treatments of female sexual dysfunction situated bremelanotide among current and emerging therapies for premenopausal HSDD [13], and a 2025 review of emerging approaches to managing vasomotor and sexual symptoms discussed it within contemporary management strategies [14]. A 2026 multidisciplinary recommendations paper on the evaluation and management of HSDD in women addressed evidence-based use of approved pharmacotherapies including bremelanotide [15].